To examine the association between selective serotonin reuptake inhibitor (SSRI) use and mortality, postoperative complications, and quality of in-hospital care in hip fracture patients.
Introduction
Hip fracture is a frequent surgical procedure among the elderly. 1 It correlates with high medical costs and health care utilization 2 and confers increased risk of mortality. 3 Thirty-day mortality in elderly surgically treated hip fracture patients is 10% and
Patients and methods setting and design
The study is a nationwide cohort study using prospectively collected data from Danish medical registries covering all Danish citizens; approximately 5.7 million people. 15 The health care system in Denmark is tax-funded, and all citizens have equal access to health care services.
Data sources
The Danish Multidisciplinary Hip Fracture Registry 16 has routinely registered comprehensive clinical data on all patients aged 65 years or older with first-time hip fracture admitted to any orthopedic department in Denmark since 2004. Data include detailed pre-and postoperative data, as well as data on quality of in-hospital care represented by process-performance measures. The Danish Civil Registration System 17 established in 1968 holds data on date of birth, vital status, and migration on all individuals in Denmark. Every citizen has a unique civil personal registration number, which allows for individual-level linkage across all Danish registries. The Danish National Patient Registry 18 contains data on civil personal registration number, hospital admission and discharge diagnosis codes, and diagnostic and surgical procedure codes from all Danish somatic hospitals since 1977. Diagnoses were coded using the ICD-8 until the end of 1993 and ICD-10 thereafter. The Danish National Database of Reimbursed Prescriptions 19 tracks reimbursed medicine dispensing at all community pharmacies and hospital-based outpatient pharmacies in Denmark since 2004. The database holds data on civil personal registration number, Anatomical Therapeutic Chemical code, redemption date, item quantity, pack size, defined daily dose, dose form, and generic substitution done at pharmacy.
Participants
Patients aged 65 years or older undergoing surgical treatment for hip fracture between 2004 and 2016 were identified in the Danish Multidisciplinary Hip Fracture Registry. The study period was subsequently restricted to patients registered between January 1, 2006, and December 31, 2016 , to ensure at least 2 years prescription history. Patients with missing data on operation delay (n=119) were excluded. In total, 68,487 first-time hip fracture patients who received surgery from 2006-2016 were available for analyses. 
Variables Exposure
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ssri use and adverse outcomes in hip fracture patients one prescription between 91 and 365 days, and non-users redeemed no prescriptions within 365 days before hip fracture surgery.
Outcomes
Several outcomes occurring after hip fracture surgery were examined separately. First, all-cause 30-day mortality was ascertained from the Civil Registration System. Second, postoperative complications were ascertained from the Danish National Patient Registry. The following postoperative complications were examined: 1) any unplanned readmission, 2) any reoperation, 3) cardiovascular events including VTE, MI, and stroke, and 4) major bleeding defined as intracranial bleeding, gastrointestinal bleeding, or urinary/lung bleeding within 30 days of surgery. Third, quality of in-hospital care represented by process-performance measures 20 including preoperative optimization, operation delay, mobilization within 24 hours postoperatively, basic mobility assessment at admission and discharge, nutritional risk assessment, osteoporosis prophylaxis, and future fall prophylaxis were obtained from the Danish Multidisciplinary Hip Fracture Registry.
Covariates
Operation year, housing, BMI, fracture type, operation type, and operation delay information was assessed from the Danish Multidisciplinary Hip Fracture Registry. Four categories comprising housing information were created: own accommodation, residential institution, homeless, and unknown. Likewise, four categories based on BMI values were created: underweight (BMI <18.5 kg/m 2 ), normal weight (BMI ≥18.5 <25 kg/m 2 ), overweight or obese (BMI ≥25 kg/m 2 ), and unknown. Age, gender, and marital status were obtained from the Danish Civil Registration System. Comorbidities were identified using the Danish National Patient Registry. Overall comorbidity was summarized according to the original Charlson Comorbidity Index (CCI) score. The CCI was categorized as low (score 0), medium (score 1-2), and high (score ≥3) comorbidity score, slightly modified compared with the original CCI. 21 The following medications were assessed from the Danish National Database of Reimbursed Prescriptions: non-steroidal anti-inflammatory drugs, corticosteroids, anticoagulants, statins, non-SSRI antidepressants, and antipsychotics. Use of each medication was defined as follows: current users redeemed one prescription within 90 days, former users redeemed one prescription between 91 and 365 days, and non-users redeemed no prescriptions within 365 days before hip fracture surgery. All codes defining study variables are available in Tables S1-S3 .
Statistical methods
Main analyses
Patient characteristics were tabulated according to SSRI use. All patients were followed from operation date to death, any unplanned readmission, any reoperation, cardiovascular event, bleeding event, or up to 30 days. Kaplan-Meier curves of the three SSRI exposure groups were plotted depicting the absolute mortality risk over time. The cumulative incidence of postoperative complications was estimated treating death as a competing risk. Crude and adjusted HRs with 95% CIs of death and postoperative complications within 30 days were estimated using Cox regression analysis comparing current and former SSRI users with non-users. The mortality model was evaluated for effect modification by age and gender. Readmission outcome data were only available for patients operated on from January 1, 2011 onward, thus readmission analyses were restricted to patients operated on between January 1, 2011 and December 31, 2016 . RRs of quality of in-hospital care were estimated using Poisson regression analysis. The process-performance measures representing quality of in-hospital care were introduced in the Danish Multidisciplinary Hip Fracture Registry at various times. Therefore, the analyses regarding the quality of in-hospital care were performed only in hip fracture patients operated on between January 1, 2015 and December 31, 2016. Potential confounder assessment was done using a directed acyclic graph ( Figure S1 ). 22 All adjusted analyses accounted for age, gender, marital status, operation year, comorbidities, other medication, and clustering by unit setting.
sensitivity analysis
Two sensitivity analyses were performed to test the robustness of the results. First, missing BMI values were imputed using multiple imputation (Supplementary materials). 23 Missing housing data were not imputed due to lack of predictors. Second, the exposure definition was changed to address potential compliance problems; current SSRI users redeemed two prescriptions within 2 years, of which one prescription was redeemed within 8 months before hip fracture, former users redeemed two prescriptions between 8 months and 2 years, and non-users redeemed one or no prescriptions within 2 years before hip fracture. 
Mortality
Overall, 7,295 hip fracture patients died within the first 30 days following hip fracture surgery. Mortality was higher in current (13%) and former (12%) users compared with non-users (10%) ( Figure 1 and Table 2 ). Compared with nonusers, the adjusted HR was 1.16 (1.10-1.21) in current users and 1.15 (1.04-1.27) in former users ( Table 2) . We found no effect modification by age and gender of the relation between SSRI use and mortality.
readmission and reoperation 
Quality of in-hospital care
The analyses included 11,363 patients operated on during 2015-2016. Figure 2 shows a marginally higher chance of assessment of basic mobility at discharge, osteoporosis prophylaxis, and future fall prophylaxis in former SSRI users compared with non-users. Overall, there was no association between current and former SSRI use and quality of inhospital care (Table S4 ).
sensitivity analysis
The HRs of mortality did not materially change after multiple imputation of missing BMI values and adjustment for BMI (Tables S5 and S6 ). Changing the exposure definition, we identified 14,530 (21%) current SSRI users, 1,116 (2%) former users, and 52,841 (77%) non-users. Patient characteristics in the new exposure groups were similar to the patient characteristics of the exposure groups used in the main analysis and the HRs of mortality were similar to the main analysis results (Tables S7 and S8 ).
Discussion
In this nationwide cohort study of hip fracture surgery patients, 30-day mortality and overall readmission were elevated for both current and former SSRI users. Those currently using SSRIs had an increased reoperation risk compared with non-users. However, SSRI use was not associated with increased risk of cardiovascular and bleeding complications and inferior quality of in-hospital care.
strengths and limitations
The strengths of this study are the use of well-established, well-validated, and prospectively collected data from Danish population-based registries with complete follow-up. 19, [24] [25] [26] The registries originate from a tax-supported and uniformly organized health care system, reducing the risk of selection bias. The validity of the hip fracture diagnosis is high, 27, 28 and the complete follow-up reduces the risk of differential misclassification. In general, our study included all elderly hip fracture patients aged 65 years or older in Denmark between 2006 and 2016. These patients are similar regarding age and gender to those included in other studies on hip 
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Bruun et al fractures in the elderly. 4, 7 To date, this is the largest study examining the association between SSRI use and mortality, postoperative complications, and quality of in-hospital care in hip fracture patients.
We gathered comprehensive data on potential confounders including complete in-hospital comorbidity history compiled in the CCI 26 and history of specific diseases. However, we did not have information on the severity of diseases included in the CCI, on diseases treated in primary care, which were not severe enough to warrant a hospital diagnosis, or information on the underlying disease indication for SSRI prescription. However, we included information on 
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ssri use and adverse outcomes in hip fracture patients other medication, which may indicate treatment of conditions not captured in the CCI. The registries we used did not contain information on socioeconomic status, smoking, alcohol use, and other lifestyle factors. Furthermore, almost half of the patients were missing data on housing, making control of confounding difficult. Thus, we were not able to control for the potential confounding of social deprivation and lack of these data may have resulted in unmeasured and residual confounding. Information on comorbidities, other medication, marital status, and unit setting may contribute to control of confounding, but is not an adequate measure of social deprivation. We included former SSRI users as a negative control. That is, we anticipated that former users were more similar to current users than non-users regarding potential confounding factors such as socioeconomic status and lifestyle factors.
Thus, if the effect of SSRI exposure on mortality was caused by the medication itself, we would anticipate only seeing an effect in current users and not in former users. However, this was not the case, and the observed association between SSRI use and mortality may rather be caused by underlying risk factors. 29 We did not have information about compliance. In our study, non-compliance would cause a misclassification of non-users as users, and therefore the observed association between SSRI use and mortality, readmission, or reoperation risk might actually be higher. However, as the patients redeemed the prescriptions, our estimates most likely reflect actual drug use. Even considering misclassification, dispensed prescriptions are considered a good measure of medication intake. 30 Furthermore, we had no data on in-hospital medication use. This may not have influenced the outcome 
Comparison with other studies
We observed an equally increased mortality risk in current and former SSRI users. This suggests that rather than being a risk factor in itself, SSRI use may be a marker of underlying risk factors such as psychiatric illness, socioeconomic status, and lifestyle factors (smoking, alcohol misuse, and physical inactivity). These results are consistent with those obtained by Auerbach et al, showing an increased mortality in SSRI users compared with non-users after major surgery, including approximately 2% hip fracture surgeries. 12 However, the association found by Auerbach et al was attenuated in patients with depression suggesting that the underlying psychiatric indication for SSRI use may explain the increased risk rather than SSRIs in itself. 12 A meta-analysis by Maslej et al found an increased mortality in antidepressant users compared to non-users in the general population independent of treatment indication. 31 The most common indications for SSRI treatment are depression and anxiety 10 and a systematic review by Eaton et al showed that depression and anxiety correlate with increased mortality. 32 Mortality in hip fracture patients may also be influenced by socioeconomic status, 33 and Marinacci et al found an association between lower education level and mortality. 34 Lower education level is further associated with increased risk of psychiatric admission due to schizophrenia, alcoholism, drug dependency, affective psychosis, neurosis, and personality disorder. 35 Finally, Seitz et al found no difference in 30-day mortality between current (9.1%) and former (9.4%) serotonergic antidepressant users undergoing hip fracture surgery. 36 However, they did not include a non-user group, which distorts the association between SSRI use and mortality.
Our findings of an increased overall readmission risk in current and former SSRI users compared with non-users is consistent with the findings reported by Auerbach et al in major surgery patients. In their study, this association persisted in patients receiving SSRIs for depression, but not in patients receiving SSRIs for other reasons. 12 This Another important finding was that current SSRI users had an increased reoperation risk compared with non-users, whereas the risk was not elevated in former users. A possible explanation for this could be that SSRI use may increase the likelihood of complications necessitating reoperation. There are different reasons for performing reoperation, eg, wound dehiscence, infection, and bleeding, 20 and these complications may be more frequent in SSRI users. Gärtner et al found an association between SSRI use and reoperation due to bleeding after breast cancer surgery. 38 However, Tully et al showed no association between serotonergic antidepressant use and reoperation due to infection or bleeding after coronary artery bypass graft surgery. 39 Further research is needed to establish the association between SSRI use and reoperation risk due to different causes in hip fracture patients.
We found little evidence of an association between SSRI and the risk of VTE, MI, stroke, and bleeding. To our knowledge, no other studies have investigated the association between SSRI use and the previously mentioned postoperative complications following hip fracture surgery. Auerbach et al found an association between SSRI use and postoperative bleeding in major surgery patients. However, they had a broader bleeding definition, including bleeding following procedure, and they included both acute and elective operations. 12 Tully et al showed no association between SSRI use and MI, stroke, or bleeding after coronary artery bypass graft surgery, 39 supporting our findings. The present study did not find any difference between SSRI non-users and users regarding quality of in-hospital care. This is important and in line with efforts of European governments to reduce social inequality in treatment of patients. 40 However, we have no information on quality of patient care outside hospital settings. Previous research suggests lower 30-day mortality in hip fracture patients who received higher quality of care. 5 Quality of in-hospital care may not explain the increased mortality associated with SSRI use in our study.
Implications of findings
One issue emerging from our findings is the question about discontinuation of SSRI treatment after hip fracture surgery. Since hip fracture is an acute condition, it is not possible to stop treatment before surgery. Our analysis suggests that stopping SSRI treatment after surgery would not change the mortality and overall readmission since these were similar in current and former users compared with non-users. We found that overall reoperation was augmented in current users, but not in former users compared with non-users. However, pausing SSRI treatment without a complete discussion of the risks and benefits is unwarranted. Our findings call for increased clinical awareness of hip fracture patients using SSRIs as they may have an increased risk of mortality, unplanned readmission, and reoperation. This patient group may be more prone to adverse outcomes after surgery regardless of the indication for SSRI treatment and may benefit from improved models of care. The follow-up care in Denmark is carried out by the municipality. Our findings suggest that hip fracture patients currently or formerly using SSRIs may benefit from closer follow-up and better communication between hospital, municipality, and general practitioner. However, the content and implementation of such improvements are beyond the scope of this paper. In future studies, it may be relevant to investigate how social deprivation influences surgical outcomes for these patients.
Conclusion
Thirty-day mortality and overall readmission in hip fracture patients were elevated in both current and former SSRI users compared with non-users. Those currently using SSRIs had an increased overall reoperation risk compared with nonusers. However, SSRI use was not associated with increased risk of cardiovascular and bleeding complications and lower quality of in-hospital care.
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Sensitivity analyses Multiple imputation Methods
In the multiple imputation model, we included all variables that were in the subsequent analysis model: selective serotonin reuptake inhibitors (SSRIs), age, gender, marital status, operation year, BMI, comorbidities, and other medication. Furthermore, some auxiliary variables such as operation delay, fracture type, operation type, and postoperative complications were included. Imputation of BMI values was done using truncated regression creating 20 imputed datasets. After imputation, the association between SSRI use and mortality was estimated in each imputed dataset. The measures of association from each imputed dataset were combined using Rubin's rule. 
